Skip to main content
SpringerLink
Log in

Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 446 Accesses

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has significantly improved the outcome of patients with acute myeloid leukemia (AML). However, the relapse rate is still high, accounting for about half of treatment failures. Administration of maintenance therapy after allo-HSCT is therefore needed to prevent relapse. Different strategies and cellular therapies after allo-HSCT have been initiated as maintenance therapy to enhance graft-versus-leukemia effects, reduce the relapse rate, and eventually improve OS. In this chapter, we will review the current maintenance therapy following allo-HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zuckerman T, Rowe JM. Transplantation in acute myeloid leukemia. Hematology/oncology clinics of North America. 2014;28:983–94.

    PubMed  Google Scholar 

  2. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2015;21:454–9.

    PubMed  Google Scholar 

  3. Lee CJ, Savani BN, Mohty M, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019;54:519–30.

    PubMed  Google Scholar 

  4. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Ray RJ, Paige CJ, Furlonger C, et al. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. European journal of immunology. 1996;26:1504–10.

    CAS  PubMed  Google Scholar 

  6. Bacher U, Haferlach C, Kern W et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood 2008;111:2527-2537.

    Google Scholar 

  7. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.

    CAS  PubMed  Google Scholar 

  8. Antar AI, Otrock ZK, Jabbour E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34:682–96.

    PubMed  Google Scholar 

  9. Weis TM, Marini BL, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Critical reviews in oncology/hematology. 2019;141:125–38.

    PubMed  Google Scholar 

  10. Weisberg E, Roesel J, Furet P, et al. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes & cancer. 2010;1:1021–32.

    CAS  Google Scholar 

  11. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Burchert A, Bug G, Fritz LV, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38:2993–3002.

    PubMed  Google Scholar 

  13. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. The Lancet Oncology. 2020;21:1201–12.

    CAS  PubMed  Google Scholar 

  14. Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105:1507–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Pratz KW, Rudek MA, Smith BD, et al. A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2020;26:300–6.

    CAS  PubMed  Google Scholar 

  16. Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone marrow transplantation. 2020;

    Google Scholar 

  17. Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. Blood. 2019;133:840–51.

    CAS  PubMed  Google Scholar 

  18. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001;19:1485–92.

    CAS  PubMed  Google Scholar 

  19. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60.

    CAS  PubMed  Google Scholar 

  20. Sandmaier BM, Khaled S, Oran B, et al. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93:222–31.

    CAS  PubMed  Google Scholar 

  21. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31:1530–8.

    CAS  PubMed  Google Scholar 

  22. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31:3681–7.

    CAS  PubMed  Google Scholar 

  23. Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML. Blood. 2018;132:598–607.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhou F, Ge Z, Chen B. Quizartinib (AC220): a promising option for acute myeloid leukemia. Drug design, development and therapy. 2019;13:1117–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. The Lancet. Oncology. 2018;19:889–903.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. 2019;20:984–97.

    CAS  PubMed  Google Scholar 

  27. Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130:2373–6.

    CAS  PubMed  Google Scholar 

  28. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012;379:1508–16.

    CAS  PubMed  Google Scholar 

  29. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30:3924–31.

    CAS  PubMed  Google Scholar 

  30. Molica M, Breccia M, Foa R, et al. Maintenance therapy in AML: The past, the present and the future. Am J Hematol. 2019;94:1254–65.

    PubMed  Google Scholar 

  31. Masarova L, Kantarjian H, Garcia-Mannero G, et al. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Advances in experimental medicine and biology. 2017;995:73–95.

    CAS  PubMed  Google Scholar 

  32. Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. The Journal of clinical investigation. 2020;130:1552–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nature medicine. 2019;25:1064–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature reviews. Genetics. 2018;19:371–84.

    CAS  PubMed  Google Scholar 

  35. Duchmann M, Itzykson R. Clinical update on hypomethylating agents. International journal of hematology. 2019;110:161–9.

    PubMed  Google Scholar 

  36. Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. International journal of hematology. 2018;107:138–50.

    CAS  PubMed  Google Scholar 

  37. Appelbaum FR. Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Best practice & research. Clinical haematology. 2019;32:101109.

    Google Scholar 

  38. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908–18.

    CAS  PubMed  Google Scholar 

  39. Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood advances. 2020;4:5580–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Maples KT, Sabo RT, McCarty JM, et al. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leukemia & lymphoma. 2018;59:2836–41.

    CAS  Google Scholar 

  41. Pusic I, Choi J, Fiala MA, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2015;21:1761–9.

    CAS  PubMed  Google Scholar 

  42. Ma Y, Qu C, Dai H, et al. Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia. Bone marrow transplantation. 2020;55:1206–8.

    PubMed  Google Scholar 

  43. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7:445–50.

    CAS  PubMed  Google Scholar 

  44. Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood. 2004;104:2124–33.

    CAS  PubMed  Google Scholar 

  45. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. The New England journal of medicine. 2016;375:143–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Berthon C, Driss V, Liu J, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer immunology, immunotherapy: CII. 2010;59:1839–49.

    CAS  PubMed  Google Scholar 

  47. Albring JC, Inselmann S, Sauer T, et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone marrow transplantation. 2017;52:317–20.

    CAS  PubMed  Google Scholar 

  48. Toprak SK. Donor lymphocyte infusion in myeloid disorders. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis. 2018;57:178–86.

    PubMed  Google Scholar 

  49. Rautenberg C, Germing U, Haas R, et al. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. International journal of molecular sciences. 2019:20.

    Google Scholar 

  50. Sterling C, Webster J. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. American journal of hematology. 2020;95:529–47.

    PubMed  Google Scholar 

  51. Jedlickova Z, Schmid C, Koenecke C, et al. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone marrow transplantation. 2016;51:663–7.

    CAS  PubMed  Google Scholar 

  52. Yan C-H, Liu D-H, Liu K-Y, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256–62.

    CAS  PubMed  Google Scholar 

  53. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.

    CAS  PubMed  Google Scholar 

  54. Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123:3855–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood reviews. 2019;34:67–83.

    CAS  PubMed  Google Scholar 

  56. Bachanova V, Miller JS. NK cells in therapy of cancer. Critical reviews in oncogenesis. 2014;19:133–41.

    PubMed  PubMed Central  Google Scholar 

  57. Handgretinger R, Schilbach K. The potential role of γδ T cells after allogeneic HCT for leukemia. Blood. 2018;131:1063–72.

    CAS  PubMed  Google Scholar 

  58. Hu Y, Cui Q, Luo C, et al. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications. Blood reviews. 2016;30:179–88.

    CAS  PubMed  Google Scholar 

  59. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14:4.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Molecular therapy: the journal of the American Society of Gene Therapy. 2013;21:2122–9.

    CAS  PubMed  Google Scholar 

  62. Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica. 2019;104:1302–8.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of Interest Statement

The authors declare no conflicts of interests.

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Center, School of Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

    Yong-Xian Hu

  2. Department of Hematology, Leukemia Center, College of Medicine, Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

    Hong-Hu Zhu

Authors
  1. Yong-Xian Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong-Hu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong-Hu Zhu .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hu, YX., Zhu, HH. (2023). Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_14

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation